ForPatients
by Roche

Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Safety and Pharmacokinetics of RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Trial Status	Trial Runs In	Trial Identifier
Not yet recruiting		NCT07558915 GO46140

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

An Open-Label, Multicenter, Phase Ia/b Study Evaluating the Safety and Pharmacokinetics of RO7851624 in Patients With Relapsed/Refractory Multiple Myeloma

Trial Summary:

This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators [IMiDs], and anti-cluster of differentiation 38 [anti-CD38] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT07558915 GO46140
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	#18 Years	No

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Life expectancy of at least 12 weeks.
- Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.

- Measurable disease.

Exclusion Criteria:

- Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to #rst dose of study treatment.
- Autologous stem cell transplant (SCT) with insufficient time prior to #rst dose of study treatment.
- Prior allogeneic SCT.
- Prior solid organ transplantation.